| Zacks Company Profile for Armata Pharmaceuticals, Inc. (ARMP : AMEX) |
|
|
| |
| • Company Description |
| Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California.
Number of Employees: 60 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $2.27 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 17,516 shares |
| Shares Outstanding: 36.19 (millions) |
| Market Capitalization: $82.16 (millions) |
| Beta: 0.94 |
| 52 Week High: $3.42 |
| 52 Week Low: $0.90 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
12.94% |
8.71% |
| 12 Week |
84.55% |
55.23% |
| Year To Date |
22.70% |
14.91% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Deborah Birx - Chief Executive Officer and Director
Robin Kramer - Chairman
David D. House - Senior Vice President; Finance and Principal Finan
Jules Haimovitz - Director
Odysseas D. Kostas - Director
|
|
Peer Information
Armata Pharmaceuticals, Inc. (CORR.)
Armata Pharmaceuticals, Inc. (RSPI)
Armata Pharmaceuticals, Inc. (CGXP)
Armata Pharmaceuticals, Inc. (BGEN)
Armata Pharmaceuticals, Inc. (GTBP)
Armata Pharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 04216R102
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
|
|
Share - Related Items
Shares Outstanding: 36.19
Most Recent Split Date: 5.00 (0.07:1)
Beta: 0.94
Market Capitalization: $82.16 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.50 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-1.94 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/12/25 |
|
|
|
| |
